Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients

Background: Tocilizumab (TCZ), a monoclonal antibody against the most prevalent cytokine interleukin-6 (IL-6), is an emerging therapeutic option for COVID-19 infections. The present study was undertaken to assess the therapeutic response of TCZ therapy in severely or critically ill COVID-19 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhandari, Sudhir, Rankawat, Govind, Singh, Ajeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991771/
https://www.ncbi.nlm.nih.gov/pubmed/33790504
http://dx.doi.org/10.5005/jp-journals-10071-23747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991771/
https://www.ncbi.nlm.nih.gov/pubmed/33790504
http://dx.doi.org/10.5005/jp-journals-10071-23747

Ejemplares similares